
Dermatology
Latest News

UV Phototherapy: Utilization in Patients with Dermatologic Disease, Co-Medications

New Patient-Reported, Quality of Life Assessment Tool Developed for Acne Patients
Latest Videos

CME Content
More News

Experts discuss the landscape of IL therapies for the treatment of psoriasis, highlighting their improved safety and efficacy over prior agents.

Experts discuss the use of TNF blockers in treating plaque psoriasis and their limited but important uses today.

TJ Chao and Kristine Kucera, PA’s go into dept of the recent developments in the systemic oral space of plaque psoriasis.

Physician assistants TJ Chao and Kristine Kucera discuss how the understanding of plaque psoriasis has changed over time and is now considered a systemic disease.

The FDA announcement on bimekizumab’s supplemental Biologics License Application followed the phase 3 BE HEARD I and II studies’ conclusion.

This analysis was conducted to evaluate the burden and disease characteristics of all 3 types of HAE among a set of Canadian patients.

In this review of the top stories in dermatology in March, several were highlighted such as the recent report on benzene in skincare products and the FDA’s approval of spesolimab for generalized pustular psoriasis.

In this interview, Del Rosso expresses his personal views on the recent report of benzene in benzoyl peroxide acne products.

Experts discuss the plethora of treatment options for psoriasis, including topicals, oral therapies, phototherapy, and biologics.

Dermatology physician assistants are talking about the evolving role of their profession in taking care of patients with plaque psoriasis.

A patient shares her journey to the diagnosis of generalized pustular psoriasis (GPP) and her care with dermatologist Dr Scott Boswell.

Advances practice providers TJ Chao, MPAS, PA-C and Kristine Kucera, PA-C, MPAS, DHS discuss the recent development in the treatment landscape of plaque psoriasis.

Chovatiya spoke in this post-AAD interview to some of the major takeaways in psoriasis research, highlighting deucravacitinib, bimekizumab, and other therapies.

Following this analysis, the conclusions provide more information on the views of potential dermatology patients on the future of their own medical images by artificial intelligence systems.

An expert in dermatology provides insight on approaching treatment in patients with plaque psoriasis who have a low BSA involvement, but with symptoms that present in difficult-to-treat areas.

Dr April W. Armstrong comments on patient selection for oral systemic treatments for plaque psoriasis management.

The FDA identified high concentration of lidocaine across marketed, over-the-counter topical products from 6 different companies.

In this analysis from the UK, the DDPS led to improved pathway management which also achieved lower service demand and smaller waiting lists for dermatologists.

This segment of Cohen’s interview from AAD covered the other talk given by Cohen titled ‘Knowing Lichenoid Dermatoses: Common Pathways and Treatments.’

April W. Armstrong, MD, MPH, shares her experience using oral systemic treatments in clinical practice for the management of plaque psoriasis.

An expert in dermatologic conditions examines laboratory requirements for initiating deucravacitinib in patients with moderate-to-severe plaque psoriasis and the impact of deucravacitinib on the treatment landscape.

These data indicate that, despite the promise held by AI in dermatological care improvement, further evaluation of training, validation, and ethical issues must be done before it is integrated.

These data highlight the risk of anxiety and depression among dermatologists, with notable findings based on gender differences observed among clinicians.

New data suggest children with atopic dermatitis and comorbid ADHD are nearly 3 times more likely to struggle with memory compared to those with just ADHD.

Counting down the most impactful news at major medical meetings, it’s the HCPLive Five! This edition shares 5 important updates from the American Academy of Dermatology (AAD) 2024 meeting.

















































